CA
NZ
UK
AU
IND
US
DaVita (NYSE:DVA) shares traded down 5.65% to $176.43 as the broader sector hit a record high. The healthcare sector was up roughly 1.8%, and Oppenheimer upgraded healthcare equipment and services to overweight. Volume was well above average.
Elevance Health (NYSE:ELV) shares traded up 2.02% to $438.94 as investors positioned for its Q3 report due Wednesday. Oppenheimer upgraded health care equipment and services to overweight and named Elevance a buy-rated pick, adding to a defensive rotation that has taken the sector near …
Freenome (NASDAQ:FRNM) shares traded up 10.61% to $13.90 after the company launched SimpleScreen Lung, a laboratory-developed blood test for adults ages 50 to 80 with a smoking history of at least 20 pack-years who are not currently in guideline-recommended screening.
Eli Lilly (NYSE:LLY) shares traded up 4.26% to $1,293.20 as investors digested a positive opinion from a European Medicines Agency committee on Foundayo, the company's oral obesity pill. Goldman Sachs raised its price target to $1,413 from $1,371, and BofA lifted its target to …
Hims & Hers (NYSE:HIMS) shares traded up 5.54% to $29.71 after the telehealth company announced its launch in Germany, including its weight management offering and deeper investment in men's health. The launch builds on its international expansion after the June Eucalyptus deal.
Johnson & Johnson (NYSE:JNJ) shares traded up 2.08% to $259.06 after the company announced the U.S. launch of its Shockwave C2 Aero Fly Coronary IVL Catheter. The device delivers pulses at 2 Hz, cutting treatment time to 115 seconds from 230 seconds with earlier …
Merck (NYSE:MRK) shares traded up 2.99% to $147.93 as a broad healthcare rally lifted the sector to record highs. Investors rotated toward defensives as oil eased and technology names sold off last week. The move follows a 1.6% pullback on Monday.
Moderna (NASDAQ:MRNA) shares traded up 5.78% to $240.00 as investors positioned for full Phase 3 data on intismeran, its personalized cancer vaccine co-developed with Merck (NYSE:MRK). The INTerpath-001 melanoma readout is due at ESMO.
Moleculin Biotech (NASDAQ:MBRX) shares traded up 20.19% to $6.37 after the company released a new CEO Corner segment. In it, CEO Walter Klemp discusses progress in the Phase 2/3 MIRACLE trial of Annamycin with high-dose cytarabine in second-line relapsed or refractory acute myeloid leukemia.
Molina (NYSE:MOH) shares traded up 4.48% to $219.63 ahead of its Q3 report due after the close on Wednesday. The healthcare sector hit a record high, and peers moved higher, with UnitedHealth (NYSE:UNH) up about 2.5% and Cigna (NYSE:CI) up about 2%. Oppenheimer's upgrade …
Please wait processing your request...